Rhumbline Advisers Increases Position in Progenics Pharmaceuticals, Inc. (PGNX)

Share on StockTwits

Rhumbline Advisers boosted its position in shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 9.2% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 179,714 shares of the biotechnology company’s stock after buying an additional 15,080 shares during the period. Rhumbline Advisers’ holdings in Progenics Pharmaceuticals were worth $1,445,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in PGNX. Millennium Management LLC purchased a new stake in shares of Progenics Pharmaceuticals during the fourth quarter valued at approximately $169,000. Virginia Retirement Systems ET AL grew its holdings in shares of Progenics Pharmaceuticals by 61.7% during the first quarter. Virginia Retirement Systems ET AL now owns 55,300 shares of the biotechnology company’s stock valued at $413,000 after buying an additional 21,100 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Progenics Pharmaceuticals by 11.1% during the first quarter. Schwab Charles Investment Management Inc. now owns 361,621 shares of the biotechnology company’s stock valued at $2,698,000 after buying an additional 36,265 shares during the last quarter. Eagle Asset Management Inc. grew its holdings in shares of Progenics Pharmaceuticals by 7.5% during the first quarter. Eagle Asset Management Inc. now owns 4,470,838 shares of the biotechnology company’s stock valued at $33,352,000 after buying an additional 310,078 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Progenics Pharmaceuticals by 268.7% during the first quarter. JPMorgan Chase & Co. now owns 326,562 shares of the biotechnology company’s stock valued at $2,436,000 after buying an additional 237,992 shares during the last quarter. 88.74% of the stock is owned by institutional investors and hedge funds.

Shares of PGNX stock opened at $5.62 on Friday. Progenics Pharmaceuticals, Inc. has a 12-month low of $5.01 and a 12-month high of $9.42. The company has a current ratio of 6.34, a quick ratio of 6.34 and a debt-to-equity ratio of 0.68.

Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its earnings results on Tuesday, July 31st. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.02). Progenics Pharmaceuticals had a negative return on equity of 94.45% and a negative net margin of 341.41%. The company had revenue of $3.88 million during the quarter, compared to analysts’ expectations of $3.30 million. equities research analysts anticipate that Progenics Pharmaceuticals, Inc. will post -0.64 earnings per share for the current year.

PGNX has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 11th. BidaskClub cut shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 5th. Jefferies Financial Group restated a “buy” rating and issued a $13.00 target price on shares of Progenics Pharmaceuticals in a report on Wednesday, August 1st. ValuEngine upgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 23rd. Finally, Needham & Company LLC restated a “strong-buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a report on Wednesday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Progenics Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $11.69.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.

Read More: Calculate Your Return on Investment (ROI)

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply